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Abstract 
Aim of Study: Redo patient undergoing valve surgery are always a challenge for both cardiac surgeon and 
anesthesiologists. Mix blood cardioplegia has had a profound impact on cardiac surgery. but there have been few 
studies on its use in mitral valve replacement, especially in redo patient. The purpose of this study was to determine 
whether mix blood cardioplegia offers any advantages in redo patient undergoing mitral valve 
replacement.Patients and Methods:  20 patient, who have had a previous mitral valve surgery and were scheduled 
for mitral valve replacement with or without tricuspid repair, were randomized retrospectively to one of two groups 
of 10 with different technique of myocardial protection: group A (10 patients) had cold crystalloid cardioplegia, 
and group B(10 patients) had mix blood cardioplegia, a technique modified on our clinic condition (made by 
mixing  400-500ml oxygenated blood from oxygenator  and 10ml KCL 7.5%) . Systemic hypothermia was 28°C 
in Group A and between 32°C and 33°C in Group B. The results were primarily assessed on the basis of clinical 
outcome, such as hematocrit level intra and post CPB, maximum dose of inotropic support, spontaneous rhythm 
recovery after aortic cross clamping, length of intensive care unit stay and secondly on postoperative blood loss 
and blood requirements. Results: There were no preoperative or operative differences between the groups with 
regard to age, sex, diagnosis, rhythm, New York Heart Association functional class, left ventricular ejection 
fraction, estimated pulmonary artery systolic pressure, operation, or duration of the operation, CPB, or aortic cross 
clamping and the time when the patients underwent the first operation. There was one death in group A (10% 
mortality). The changes in hematocrit level differs significantly between the two groups on the post CPB period 
(p=0,02) There appeared to be a trend towards better spontaneous recovery of sinus rhythm after removal of the 
aortic cross clamp in group B compared with group A, the difference did reach statistical significance. (p=0.002). 
Patients on group A required more inotropic support than Group B (p=0.005). There were differences even on 
blood requirements postoperatively, more dominant these  requirement were in group A (p=0.02).Discussion: Mix 
Blood Cardioplegia had beneficial effects in clinical outcome in redo patients undergoing mitral valve replacement 
surgery. This may be due to its better preservation of high-energy phosphates and endogenous amino acids, less 
anerobic metabolic activity on reperfusion, reduced release of cardiac troponin T, and improved post-ischemic 
functional recovery.  
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Introduction 
Miocardial protection during cardiac surgery is the key point in this kind of intervention. The different techniques 
of myocardial protection has been evolved in the course of the years, making cardiac surgery more safe. This study 
is part of several years follow-up in our clinic of cardiac surgery. From many years we had made efforts to change 
the cardioplegia solution from crystalloid into blood, based on western clinics guidelines and modified on the 
conditions of our clinic. From 5 years we use successfully warm blood cardioplegia and the results are very good. 
Blood cardioplegia has had a profound impact on cardiac surgery, especially in coronary artery bypass surgery, 
but there have been few studies on its use in mitral valve replacement, especially in redo patient.  Warm blood 
cardioplegia is used to modify reperfusion injury, resulting in improved postoperative contractile function and 
decreased mortality. The purpose of this study was to determine whether mix warm blood cardioplegia offers any 
advantages in redo patients undergoing mitral valve replacement.  We designed a study to compare 2 techniques 
of myocardial protection: intermittent crystalloid cardioplegia, and intermittent mix warm blood cardioplegia. The 
results were primarily assessed on the basis of clinical outcome, and postoperative blood loss and blood 
requirements.  
 
Patients and methods  
Between January 2018 and September 2020, in Cardiac Surgery Clinic in “Mother Teresa” Hospital Center, Tirana, 
Albania, 20 patients, who have had previous mitral valve surgery, were scheduled for MVR with or without 
tricuspid repair, were randomized retrospectively to one of two groups of 10 with different technique of myocardial 
protection. In Group A (10 patients) intermittent antegrade cold crystalloid cardioplegia (4 grade C) was used.   In 
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group B, (10 patients) mix warm blood cardioplegia (MWBC) was used. Anesthesia technique were the same in 
both groups, general anesthesia.  
All operations were performed using cardiopulmonary bypass (CPB) with ascending aortic and bicaval 
cannulation. Systemic hypothermia was 28°C in Group A and between 32°C and 33°C in Group B. 
Antegrade cold crystalloid cardioplegia was injected immediately after aortic cross clamping at 15-20mLꞏkg-
1. and than at 30minutes interval. In Group B the technique MWBC was realized with our modifications on the 
condition of our clinic, the first dose was cold crystalloid (15-120ml/kg/weight), after 30 minutes a second dose 
of cardioplegia was made by mixing 400-500ml oxygenated blood from oxygenator and 10ml KCL 7.5%, and a 
third dose of the same solution after 20minutes. The MWBC temperature was gradually increased from 33°C to 
36°C by the end of the infusion. Electrical defibrillation was applied if ventricular fibrillation persisted beyond 
2min after aortic de clamping, and a temporary pacemaker was used if there was no spontaneous rhythm or if the 
patient’s heart rate was less than 50 beatsꞏmin-1. After the operation, if systolic blood pressure was lower than 90 
mm Hg and urine output less than 1 mLꞏkg-1ꞏh-1 with central venous pressure between 10 and 12 mm Hg, 
inotropic support was started. Our first choice of inotropic agent was adrenaline. 
Table 1. Preoperative and Operative Data in Patients Undergoing Mitral Valve Replacement 
Variable                     Group A(n=10)       Group B (n=10)           P-Value 
Age (years)               43+/-10  44+/-10                 0.32 
Sex (male/female)   7 / 3  8 / 2   
Diagnosis        
MS                  5  7   
MR         
Mixed MS/MR    2  1   
MR + TR    3  2   
Rhythm        
Sinus rhythm    3  5   
Atrial fibrillation                 7  5   
NYHA class        
II         
III                   9  8  
IV                    1  2   
PASP (mm Hg)                              60+/-23              63+/-19                   0.62 
Ejection fraction (%)   50+/-7               52+/-5                    0.15 
Operation        
MVR                    7  8   
MVR + tricuspid repair       3  2   
CPB time (min)                  65+/-5  60+/-5                    0.45 
Aortic cross clamp time (min)  50+/-5  55+/-5                    0.44 
Temperature during CPB (c)  28°C  32-33°C 
CPB = cardiopulmonary bypass, NYHA = New York Heart Association, PASP = pulmonary artery systolic 
pressure, MR = mitral regurgitation, MS = mitral stenosis, MVR = mitral valve replacement, TR = tricuspid 
regurgitation.   
Intraoperative and postoperative variables were used to assess primary clinical outcomes including hematocrit 
levels pre CPB, intra and post CPB period, spontaneous rhythm recovery after aortic de clamping (no requirement 
for electrical defibrillation or temporary pacemaker), maximum doses of inotrope, duration of inotropic support, 
length of intensive care unit stay, postoperative blood loss and blood requirements.  
Commutative data are expressed as the mean ± standard deviation of the mean. Analysis of the difference in 
clinical outcome between the two groups was performed using Student’s t test. 
The significance level for differences in all tests was p < 0.05. Univariate linear regression analysis was used 
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Table 2. Comparison of Clinical Outcomes      
Clinical Outcome                     GroupA (n=10)      GrupB (n=10)  p-Value 
Htc/Pre CPB (%)                 37.31  37.47    
Htc/in CPB/post first dosis (%)   23.9  24.3                             0.1 
Htc/in CPB/post second dosis (%)   21.9  24.2   0.3 
Htc/post CPB (%)                  26.4  31.8                0.02 
Spontaneous rhythm recovery (n)    1  9   0.002  
Ventriclar fibrilation after aortic declamp (n)  9  1   0.002 
Reperfusion time (min)               25+/-5                15+/-5                0.007 
Inotropic suport (adrenaline mcg/kg)                             0.08 - 0.12           0.04 - 0.08  0.005 
Perioperativ death                                                             1                  0                         10 %( mortality)
  
Intensive care stay (days)     2.9   2.1   0.3 
Blood loss (ml)                                                            600+/-100           400+/-100  0.06 
Blood transfusion     2.5   1.5   0.02 
Survival                                     9     10 
 
Results 
There were no preoperative or operative differences between the groups with regard to age, sex, diagnosis, rhythm, 
New York Heart Association functional class, left ventricular ejection fraction, estimated pulmonary artery systolic 
pressure, operation, or duration of the operation, CPB, or aortic cross clamping the time when the patients 
underwent the first operation. (Table 1). There was one death in group A (10% mortality). Clinical outcomes are 
shown in Table 2.  
The changes in hematocrit level differs significantly between the two groups on the post CPB period (p=0,02) 
There appeared to be a trend towards better spontaneous recovery of sinus rhythm after removal of the aortic cross 
clamp in group B compared with group A, the difference did reach statistical significance. (p=0.002). According 
to our protocol for postoperative care, patients in group A required more inotropic support than Group B (p=0.005). 
There were differences even on blood requirements postoperatively, more dominant these requirements were in 
group A (p=0.02). Postoperative echocardiography showed good left ventricular ejection fractions in both groups. 
There were no differences between the 2 groups in duration of ICU stays. 
 
Discussion 
The basic concept of MWBC is reduction of myocardial energy demand by maintaining cardiac arrest with 
hyperkalemic warm blood perfusate during initial reperfusion, to restore high-energy phosphates and enhance 
cellular repair after ischemic cardiac arrest. 
The beneficial effects of MWBC have been studied both experimentally and clinically. They include better 
preservation of high-energy phosphates and endogenous amino acids, less anerobic metabolic activity on 
reperfusion, reduced release of cardiac troponin T, and improved post-ischemic functional recovery1.5. Those 
effects facilitate coronary vasodilatation and accelerate early myocardial tissue oxygen saturation during warm 
reperfusion2.  
Tenpaku and colleagues demonstrated complete microtubule repolymerization after 10 min of reperfusion 
with warm blood. This mechanism may be responsible for the early and improved recovery of cardiac function 
associated with MWBC. 
Most clinical studies of MWBC have been undertaken on coronary artery bypass surgery, with more recent 
investigations on MWBC in congenital heart surgery. 
Most results have showed definite advantages in the use of MWBC, although there have been some that 
showed no beneficial effect of MWBC. 
There is some evidence that a glutamate-aspartate supplement to the MWBC (substrate-enriched 
cardioplegia) may reduce reperfusion injury and improve both metabolic and myocardial function recovery. 
Glutamate and aspartate are not available at our institute, so our MWBC was not a substrate-enriched solution, 
and it is possible that the MWBC benefits would be more obvious if this technique were employed3.4. 
Improved spontaneous rhythm recovery has also been observed with the use of MWBC. There appeared to 
be a trend towards a better cardiac rhythm recovery in the MWBC 
group (less requirement of electrical defibrillation and temporary pacemakers), the difference did reach 
statistical significance when compared with patients in the non-MWBC group. 
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